反応式
[CH3:1][C:2]1[C:3]([N:8]2[CH2:13][CH2:12][NH:11][CH2:10][CH2:9]2)=[N:4][CH:5]=[CH:6][CH:7]=1.C(O[BH-](O[C:24](=[O:26])[CH3:25])OC(=O)C)(=O)C.[Na+]>>[CH3:1][C:2]1[C:3]([N:8]2[CH2:9][CH2:10][N:11]([CH2:7][C:6]3[O:26][C:24]4[C:25](=[N:4][CH:3]=[CH:2][CH:1]=4)[CH:5]=3)[CH2:12][CH2:13]2)=[N:4][CH:5]=[CH:6][CH:7]=1参加物
3
実験手順
The product from Example 35B, 1-(3-methyl-2-pyridinyl)piperazine, and sodium triacetoxyborohydride were processed as described in Example 35C to provide the title compound. 1H NMR (CDCl3, 300 MHz) 62.68 (m, 4H), 3.29 (s, 3H), 3.58 (m, 4H), 3.79 (s, 2H), 6.41 (d, J=8.48 Hz, 1H), 6.49 (d, J=7.12 Hz, 1H), 6.85 (s, 1H), 7.18 dd, J=4.75, 8.14 Hz, 1H), 7.36 (dd, J=7.12, 8.14 Hz, 1H), 7.73 (dd, J=1.02, 8.14 Hz, 1H), 8.51 (dd, J=1.36, 4.75 Hz, 1H); MS (DCI/NH3) m/z 309.2 (M+H)+.
出典と根拠
- ORDレコード
- ord-0669a961823941a6a897f16dc1efa5ec
- 出典データセット
- uspto-grants-2006_06
- 特許番号
- US07057042B2
関連ノート
読み込み中…